12.54
+0.15(+1.21%)
Currency In USD
| Previous Close | 12.39 |
| Open | 12.38 |
| Day High | 12.77 |
| Day Low | 12.16 |
| 52-Week High | 12.76 |
| 52-Week Low | 1.01 |
| Volume | 2.41M |
| Average Volume | 5.21M |
| Market Cap | 3.88B |
| PE | -29.16 |
| EPS | -0.43 |
| Moving Average 50 Days | 6.92 |
| Moving Average 200 Days | 3.08 |
| Change | 0.15 |
If you invested $1000 in Erasca, Inc. (ERAS) since IPO date, it would be worth $719.45 as of February 21, 2026 at a share price of $12.54. Whereas If you bought $1000 worth of Erasca, Inc. (ERAS) shares 3 years ago, it would be worth $3,502.79 as of February 21, 2026 at a share price of $12.54.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Erasca to Present at Upcoming Conferences in February
GlobeNewswire Inc.
Feb 05, 2026 1:00 PM GMT
SAN DIEGO, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, to
Erasca Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
GlobeNewswire Inc.
Jan 23, 2026 9:01 PM GMT
SAN DIEGO, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, to
Erasca Announces Pricing of Upsized Public Offering of Common Stock
GlobeNewswire Inc.
Jan 22, 2026 1:54 AM GMT
SAN DIEGO, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, to